ANNX

Rating neutralAI Memo

Annexon

As of 2026-09-11/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-11 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

ANX1502 proof-of-concept results • 2026-11-30

Base target: $7 / p=45% prob

Biggest risk

The thesis depends heavily on binary clinical and regulatory outcomes. ARCHER II failure or delay could impair the largest valuation driver, while the tanruprubart evidence package may face regulatory questions. The credit facility extends runway but may introduce debt obligations, and future equity financing or ATM usage could dilute shareholders.

Invalidation

Break below $2 or thesis failure.

What would change my mind?

Multiple late-2026 milestones provide unusually dense upside optionality: pivotal geographic-atrophy data, a planned GBS BLA submission, and ANX1502 proof-of-concept results. Management also reported runway into 2028 following a $200 million credit facility, and a director purchased approximately $3.3 million of stock at $5.41 in May [#SEC-8K-2026-08-12] [#SEC-FORM4-2026-05-29].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-11

Base target

p=45%

Bull target

$16

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Multiple late-2026 milestones provide unusually dense upside optionality: pivotal geographic-atrophy data, a planned GBS BLA submission, and ANX1502 proof-of-concept results.
Management also reported runway into 2028 following a $200 million credit facility, and a director purchased approximately $3.3 million of stock at $5.41 in May [#SEC-8K-2026-08-12] [#SEC-FORM4-2026-05-29].
The stored analyst-target median is $15.50 versus the $4.14 anchor price, but the contributing analyst count and target range are unavailable, making it unsuitable as a high-confidence valuation anchor.

BearKey bullets

ANX1502 proof-of-concept data may fail to validate the oral classical-complement approach or may be insufficient to support meaningful pipeline value.
Annexon remains a development-stage biotechnology company exposed to ongoing R&D spending, commercialization buildout costs, debt-service requirements, and potential shareholder dilution.
Failure, delay, or ambiguous results from the ARCHER II Month-15 Phase 3 endpoint could materially reduce vonaprument's probability-adjusted value.

WatchKey bullets

ANX1502 proof-of-concept results

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $7 (p=45%)

Target spread vs base: +121% / -79%

Scenario probabilities

Bull Target: $16 (p=25%)Base Target: $7 (p=45%)Bear Target: $2 (p=30%)

Commentary

Company-source tone is constructive and the late-2026 milestone calendar is dense, but independent coverage is thin. Reliable post-update price reaction, analyst revisions, options positioning, short interest, employee sentiment, and sufficient social coverage are unavailable; the zero-valued fields above indicate unavailable inputs rather than neutral readings. Sentiment supports cautious monitoring rather than a high-conviction directional call.

As of 2026-09-11 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Multiple late-2026 milestones provide unusually dense upside optionality: pivotal geographic-atrophy data, a planned GBS BLA submission, and ANX1502 proof-of-concept results.
Management also reported runway into 2028 following a $200 million credit facility, and a director purchased approximately $3.3 million of stock at $5.41 in May [#SEC-8K-2026-08-12] [#SEC-FORM4-2026-05-29].

Scenarios

Bull Target (Scenario probability)

$16 / p=25% prob

Base Target (Scenario probability)

$7 / p=45% prob

Bear Target (Scenario probability)

$2 / p=30% prob

Analysis 2026-09-11 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.15

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-30
ANX1502 proof-of-concept results
Proof-of-concept data for the oral C1 inhibitor ANX1502 are expected in fall 2026. Positive results could broaden perceived platform value, although this earlier-stage program should carry less valuation weight than the Phase 3 assets [#SEC-8K-2026-08-12].
Prob 45.00% • Move 25.00% • Priced-in 20.00%
EVENT2026-12-31
ARCHER II Phase 3 geographic-atrophy data
Month-15 primary-endpoint data for vonaprument remain on track for Q4 2026. This is the largest near-term valuation catalyst and carries substantial binary clinical risk [#SEC-8K-2026-08-12].
Prob 50.00% • Move 60.00% • Priced-in 30.00%
EVENT2026-12-31
Tanruprubart U.S. BLA submission
Annexon expects to submit a U.S. BLA for tanruprubart in Guillain-Barré syndrome during Q4 2026, while its European application is under review. Submission execution and regulators' assessment of the evidence package remain key uncertainties [#SEC-8K-2026-08-12].
Prob 65.00% • Move 35.00% • Priced-in 40.00%

Risks

ANX1502 proof-of-concept data may fail to validate the oral classical-complement approach or may be insufficient to support meaningful pipeline value.
Annexon remains a development-stage biotechnology company exposed to ongoing R&D spending, commercialization buildout costs, debt-service requirements, and potential shareholder dilution.
Failure, delay, or ambiguous results from the ARCHER II Month-15 Phase 3 endpoint could materially reduce vonaprument's probability-adjusted value.
Regulators may require additional evidence for tanruprubart, delaying or preventing approval despite the planned Q4 2026 BLA submission and ongoing European review.
The peer set is loose, analyst coverage details are unavailable, and no reliable social-sentiment or post-update market-reaction evidence is present.

Peers

Symbol	Summary
CLYM	Similar-sized development-stage biotechnology comparator, useful mainly for financing and clinical-event sensitivity; no direct indication or mechanism match is established.
DSGN	Similar-market-cap biotechnology comparator with readout-driven valuation characteristics, but its programs are not established as direct operating comparables to Annexon.
JANX	Small-cap clinical biotechnology comparator that illustrates binary-data volatility; different therapeutic focus limits direct valuation comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-11

Loading AI feed…

Symbol

Summary

CLYM

Similar-sized development-stage biotechnology comparator, useful mainly for financing and clinical-event sensitivity; no direct indication or mechanism match is established.

DSGN

Similar-market-cap biotechnology comparator with readout-driven valuation characteristics, but its programs are not established as direct operating comparables to Annexon.

JANX

Small-cap clinical biotechnology comparator that illustrates binary-data volatility; different therapeutic focus limits direct valuation comparability.